Skip to main content
KBS_Icon_questionmark link-ico
Health

Neurodevelopmental Disorders Clinical Trials Centre (NDD-CTC)

Aims

We undertake clinical trials for the core symptoms and associated conditions of neurodevelopmental disorders in collaboration with industry partners, King’s clinical trials unitKHP clinical trials office, the NIHR Maudsley Biomedical Research Centre and the NIHR / Wellcome Trust King's Clinical Research Facility. 

 

Our focus

The NDD-CTC undertakes fully powered clinical trials of potential treatments identified in our clinical trials pipeline based on shiftability and other experimental studies within the department, and includes treatments for individuals with Autism spectrum conditions, Down syndrome, and intellectual disabilities.

 

Our Process

NDD-CTC Process
biomarkers1

 

Step 1:

Find biomarker of neurodevelopmental disorder or comorbid condition shared by a group of people

Shiftability2

 

Step 2:

Conduct 'shiftability study': target biomarker with dose of compound to test for response on biomarker

Biological1

 

Step 3:

Does this make a biological difference? NO - STOP

Pills_Fastfail1

Step 4:

Yes - move forward to 'Fast Fail' trial

Brain_fastfail1


Step 5:

Conduct 'Fast Fail' trial to test if we can maintain shift in the biomarker for ~weeks
NO - STOP

Pill Crop2


Step 6:

Yes - full clinical trial should be done in people we know should respond

Participants1

 

Step 7:
NDD-CTC conducts Phase II and III trials with ~hunderds of participant

Partners

NIHR Maudsley BRC logo

NIHR Maudsley Biomedical Research Centre

Project status: Ongoing

Principal investigators

Andre Strydom

Professor Andre Strydom

Professor in Intellectual Disabilities

Investigators

250-Declan-Murphy

Declan Murphy

Professor